Efter aflæggelse af Q3 regnskabet afholdte Genmabs ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Genmab indleder præsentationen sådan:
Company & Pipeline Highlights
• U.S. FDA approval of Kesimpta (ofatumumab)1 in RMS
• Epcoritamab2: 1st pt dosed in expansion cohort
• DuoBody®-CD3x5T42: FiH trial initiated
• HexaBody®-CD383: IND submitted (Oct)
• DuoBody-PD-L1x4-1BB4 (GEN1046): preliminary clinical data to be presented at SITC Annual
Meeting (Nov)
• Tisotumab vedotin5:
• innovaTV 204 presented as late-breaking abstract at ESMO
• Joint commercialization agreement
• Advances in Janssen DuoBody program
DARZALEX® (daratumumab)
• Regulatory
• U.S. FDA approval based on CANDOR
• U.S. sBLA filed based on ANDROMEDA
• Positive topline results:
• Phase 3 APOLLO study in RRMM
• Phase 3 CASSIOPEIA part 2, maintenance
• USD 2,937 million net sales by J&J in 1st 9 mo. 2020, resulting in DKK 2,898 million in royalties
